1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuropathic Pain Drugs Revenue
1.4 Market by Type
1.4.1 Global Neuropathic Pain Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tricyclic Anti-Depressants Anticonvulsants
1.4.3 Serotonin-Norepinephrine Reuptake Inhibitor
1.4.4 Capsaicin Cream
1.4.5 Local Anaesthesia
1.4.6 Opioids
1.4.7 Steroids
1.4.8 Others
1.5 Market by Application
1.5.1 Global Neuropathic Pain Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Neuropathic Pain Drugs Market Perspective (2015-2026)
2.2 Global Neuropathic Pain Drugs Growth Trends by Regions
2.2.1 Neuropathic Pain Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuropathic Pain Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Neuropathic Pain Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuropathic Pain Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Neuropathic Pain Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Neuropathic Pain Drugs Players by Market Size
3.1.1 Global Top Neuropathic Pain Drugs Players by Revenue (2015-2020)
3.1.2 Global Neuropathic Pain Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuropathic Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuropathic Pain Drugs Market Concentration Ratio
3.2.1 Global Neuropathic Pain Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Drugs Revenue in 2019
3.3 Neuropathic Pain Drugs Key Players Head office and Area Served
3.4 Key Players Neuropathic Pain Drugs Product Solution and Service
3.5 Date of Enter into Neuropathic Pain Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuropathic Pain Drugs Historic Market Size by Type (2015-2020)
4.2 Global Neuropathic Pain Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Neuropathic Pain Drugs Market Size by Application (2015-2020)
5.2 Global Neuropathic Pain Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Neuropathic Pain Drugs Market Size (2015-2020)
6.2 Neuropathic Pain Drugs Key Players in North America (2019-2020)
6.3 North America Neuropathic Pain Drugs Market Size by Type (2015-2020)
6.4 North America Neuropathic Pain Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Neuropathic Pain Drugs Market Size (2015-2020)
7.2 Neuropathic Pain Drugs Key Players in Europe (2019-2020)
7.3 Europe Neuropathic Pain Drugs Market Size by Type (2015-2020)
7.4 Europe Neuropathic Pain Drugs Market Size by Application (2015-2020)
8 China
8.1 China Neuropathic Pain Drugs Market Size (2015-2020)
8.2 Neuropathic Pain Drugs Key Players in China (2019-2020)
8.3 China Neuropathic Pain Drugs Market Size by Type (2015-2020)
8.4 China Neuropathic Pain Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Neuropathic Pain Drugs Market Size (2015-2020)
9.2 Neuropathic Pain Drugs Key Players in Japan (2019-2020)
9.3 Japan Neuropathic Pain Drugs Market Size by Type (2015-2020)
9.4 Japan Neuropathic Pain Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Neuropathic Pain Drugs Market Size (2015-2020)
10.2 Neuropathic Pain Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuropathic Pain Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Neuropathic Pain Drugs Market Size by Application (2015-2020)
11 India
11.1 India Neuropathic Pain Drugs Market Size (2015-2020)
11.2 Neuropathic Pain Drugs Key Players in India (2019-2020)
11.3 India Neuropathic Pain Drugs Market Size by Type (2015-2020)
11.4 India Neuropathic Pain Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Neuropathic Pain Drugs Market Size (2015-2020)
12.2 Neuropathic Pain Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuropathic Pain Drugs Market Size by Type (2015-2020)
12.4 Central & South America Neuropathic Pain Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Neuropathic Pain Drugs Introduction
13.1.4 Pfizer Revenue in Neuropathic Pain Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Details
13.2.2 Johnson & Johnson Business Overview
13.2.3 Johnson & Johnson Neuropathic Pain Drugs Introduction
13.2.4 Johnson & Johnson Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.2.5 Johnson & Johnson Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Neuropathic Pain Drugs Introduction
13.3.4 Sanofi Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Details
13.4.2 GlaxoSmithKline Business Overview
13.4.3 GlaxoSmithKline Neuropathic Pain Drugs Introduction
13.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.4.5 GlaxoSmithKline Recent Development
13.5 Eli Lilly
13.5.1 Eli Lilly Company Details
13.5.2 Eli Lilly Business Overview
13.5.3 Eli Lilly Neuropathic Pain Drugs Introduction
13.5.4 Eli Lilly Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.5.5 Eli Lilly Recent Development
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Details
13.6.2 Bristol-Myers Squibb Business Overview
13.6.3 Bristol-Myers Squibb Neuropathic Pain Drugs Introduction
13.6.4 Bristol-Myers Squibb Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.6.5 Bristol-Myers Squibb Recent Development
13.7 Biogen
13.7.1 Biogen Company Details
13.7.2 Biogen Business Overview
13.7.3 Biogen Neuropathic Pain Drugs Introduction
13.7.4 Biogen Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.7.5 Biogen Recent Development
13.8 Baxter Healthcare
13.8.1 Baxter Healthcare Company Details
13.8.2 Baxter Healthcare Business Overview
13.8.3 Baxter Healthcare Neuropathic Pain Drugs Introduction
13.8.4 Baxter Healthcare Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.8.5 Baxter Healthcare Recent Development
13.9 Depomed
13.9.1 Depomed Company Details
13.9.2 Depomed Business Overview
13.9.3 Depomed Neuropathic Pain Drugs Introduction
13.9.4 Depomed Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.9.5 Depomed Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Pfizer、Johnson & Johnson、Sanofi、GlaxoSmithKline、Eli Lilly、Bristol-Myers Squibb、Biogen、Baxter Healthcare、Depomed
【免責事項】
https://www.globalresearch.jp/disclaimer